RALOXIFEN THAILAND 60M	G 28 FCT
SMPC	

Die Cut size	2 Pages - 297x620mm
Created	DE 16/07/2021
Modified	DE 12/08/2021
Proof round	06
ART Code	ARTDB020649P

PRINT COLOURS

Black Black 80%

Black 20%

SUPPORT COLOURS (NO PRINT)

MINIMUM FONT SIZE ENG = 8PT; THAI = 8PT

If the above minimum font size is not acceptable for this artwork (excluding codes) please do not approve.

REGULATORY APPROVAL

COPYRIGHTS / CONTACT

This artwork and its content is copyright of Alvogen ©Alvogen 2012. All rights reserved.

Any Anthropoidea digitally or hardcopy redistribution, alternation or reproduction of part or all of the contents in any form is prohibited by other than Alvogen staff for company usage.

Main contact:

David Garcia, Artwork Director david.garcia@Alvogen.com



CELVISTA

RALOXIFENE HYDROCHLORIDE

1. NAME OF THE MEDICINAL PRODUCT

CELVISTA 60 mg film coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film coated tablet contains 60 mg raloxifene hydrochloride, equivalent to 56 mg raloxifene free base. For excipients see 6.1

3. PHARMACEUTICAL FORM

Film coated tablets. They are presented as elliptically shaped, white tablets which are imprinted with the code ALV.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

CELVISTA is indicated for the treatment and prevention of osteoporosis in postmenopausal women

Celvista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. Celvista is indicated for the reduction in risk of invasive breast cancer in CELVISTA is only for use in postmenopausal women. postmenopausal women at high risk of breast cancer.

The incidence of vertebral fractures is significantly reduced. Although the reduction in the incidence of non-vertebral fractures is not significant, the risk of a non-vertebral fracture decreases with increasing exposure to CELVISTA.

When determining the choice of CELVISTA or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see Section 5.1).

4.2 Posology and method of administration

The recommended posology is one tablet daily by oral administration, which may be taken at any time of the day without regard to meals. No dose adjustment is necessary for the elderly. Due to the nature of this disease process, CELVISTA is intended for long term use.

Generally calcium and vitamin D supplements are advised in women with a low dietary intake.

Elderly:

No dose adjustment is necessary for the elderly.

Renal impairment:

Celvista should not be used in patients with severe renal impairment (see section 4.3). In patients with moderate and mild renal impairment, Celvista should be used with caution. Hepatic impairment:

Celvista should not be used in patients with hepatic impairment (see section 4.3 and 4.4).

Paediatric population: Celvista should not be used in children of any age. There is no relevant use of Celvista in the paediatric population.

4.3 Contraindications

Must not be used in women with child bearing potential.

Active or past history of venous thromboembolic events (VTE), including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis.

Hypersensitivity to raloxifene or to any of the excipients in the tablet. Hepatic impairment including cholestasis. evere renal impairment. Unexplained uterine bleeding. CELVISTA should not be used in patients with signs or symptoms of endometrial or breast cancer as safety in these patient groups has not been adequately studied.

4.4 Special warnings and special precautions for use

Stroke: The risk-benefit balance of raloxifene in postmenopausal women with a history of stroke or other significant stroke risk factors, such as transient ischemic attack or atrial fibrillation, should be considered when prescribing raloxifene. In a study of postmenopausal women with documented coronary heart disease or at increased risk for coronary events taking raloxifene, the incidence of stroke, myocardial infarction, hospitalized acute coronary syndrome, cardiovascular mortality, or overall mortality was comparable to placebo. However, there was an increase in mortality due to stroke. The incidence of stroke mortality was 1.5 per 1000 women per year for placebo versus 2.2 per 1000 women per year for raloxifene.

Raloxifene is associated with an increased risk for venous thromboembolic events (deep vein thrombosis and pulmonary embolism) that is similar to the reported risk associated with current use of hormone replacement therapy. The risk-benefit balance should be considered in patients at risk of venous thromboembolic events or any aetiology. LELVIS IA Should be discontinued in the event of a illness or a condition leading to a prolonged period of immobilisation. Discontinuation should happen as soon as possible in case of the illness, or from 3 days before the immobilisation occurs. Therapy should not be restarted until the initiating condition has resolved and the patient is fully mobile.



were identified.

Concomitant use of vaginal estrogen preparations was commonplace in the clinical trial programme. No interaction was noted and compared to placebo there was no increased use in CELVISTA treated patients.

In vitro, raloxifene did not interact with the binding of warfarin, phenytoin, or tamoxifen.

Raloxifene should not be co-administered with cholestvramine (or other anion exchange resins), which significantly reduces the absorption and enterohepatic cycling of raloxifene.

Peak concentrations of raloxifene are reduced with co-administration with ampicillin. However, since the overall extent of absorption and the elimination rate of raloxifene are not affected, raloxifene can be concurrently administered with ampicillin.

Raloxifene modestly increases hormone-binding globulin concentrations, including sex steroid binding globulins (SHBG), thyroxine binding globulin (TBG), and corticosteroid binding globulin (CBG), with corresponding increases in total hormone concentrations. These changes do not affect concentrations of free hormones

4.6 Use during pregnancy and lactation

CELVISTA must not be taken by women of child bearing potential. Raloxifene may cause foetal harm when administered to a pregnant woman. If this medicinal product is used mistakenly during pregnancy or the patient becomes pregnant while taking it, the patient should be rmed of the potential hazard to the foetus (see Section 5.3).

It is not known whether raloxifene is excreted in human milk. Its clinical use, therefore, cannot be recommended in lactating women. CELVISTA may affect the development of the baby.

4.7 Effects on ability to drive and use machines

Raloxifene has no known effect on driving or the ability to use machinery

4.8 Undesirable effects

a. Summary of the safety profile

The clinically most important adverse reactions reported in postmenopausal women treated with Celvista were venous thromboembolic events (see section 4.4), which occurred in less than 1% of treated patients.

b. Tabulated summary of adverse reactions The table below gives the adverse reactions and frequencies observed in treatment and prevention studies involving over 13,000 women all undesirable reactions were recorded. The duration of treatment in these studies ranged from 6 to 60 months. The majority of undesirable reactions has not usually required cessation of therapy.

The frequencies for postmarketing reports were calculated from placebo-controlled clinical trials (comprising a total of 15,234 patients, 7,601 on raloxifene 60 mg and 7,633 on placebo) in postmenopausal women with osteoporosis, or established coronary heart disease (CHD) or increased risk for CHD, without comparison to the frequencies of adverse events in the placebo assignment groups. In the prevention population discontinuations of therapy due to any undesirable reaction occurred in 10.7 % of 581 CELVISTA treated patients and 11.1 % of 584 placebo-treated patients. In the treatment population discontinuations of therapy due to any clinical adverse experience occurred in 12.8 % of 2,557 CELVISTA treated patients and 11.1 % of 2,576 placebo treated patients.

The undesirable reactions associated with the use of raloxifene in clinical trials are summarized in the table below.

The following convention has been used for the classification of the adverse reactions: very common ($\ge 1/10$), common ($\ge 1/100$ to < 1/10), uncommon ($\ge 1/1,000$ to < 1/100), rare ($\ge 1/10,000$ to < 1/1,000), very rare (<1/10.000).

'n	Blood and lymphatic system disorders Uncommon: Thrombocytopenia ^a	As a selective estrogen receptor moor selective agonist or antagonist activit estrogen. It acts as an agonist on bo	
h	Nervous System Disorders Common: Headache, including migraine Uncommon: Fatal strokes	metabolism (decrease in total and LL hypothalamus or in the uterine or bre	
əs n	Vascular Disorders Very common: Vasodilation (hot flushes) Uncommon: Venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, retinal vein thrombosis Superficial vein thrombophlebitis, Arterial thromboembolic reaction ^a	Raloxifene's biological actions, like the through high affinity binding to estro- gene expression. This binding results estrogen-regulated genes in different that the estrogen receptor can regula distinct pathways which are ligand, t	
	Gastrointestinal Disorders Very common: Gastrointestinal symptoms such as nausea, vomiting, abdominal pain, dyspepsia	a) Skeletal Effects The decrease in estrogen availability to marked increases in bone resorption	
	Skin and Subcutaneous Tissue Disorders Common: Rash	Bone loss is particularly rapid for the when the compensatory increase in the	

The core adverse drug event terms for raloxifene and their frequency are **c**) shown in the following two tables:

Table 1. Frequency of venous thromboembolism in raloxifene-treated patients (60 mg/day) across placebo-controlled trials of at least 6 months in duration.

Clinical Trial	Frequency Raloxifene	Frequency Placebo
Postmenopausal women: osteoporosis treatment and prevention clinical trials	3.05/1000 patient-years (0.9% cumulative incidence) ^a	0.81/1000 patient-years (0.2% cumulative incidence) ^a
Postmenopausal women: documented coronary heart disease or at increased risk for coronary events	3.88/1000 patient-years (2.0% cumulative incidence) ^b	2.70/1000 patient-years (1.4% cumulative incidence) ^b

^a Median duration of exposure was 42 months. ^b Median duration of exposure was 61 months.

VTE includes deep venous thrombosis, and pulmonary embolism. Other venous thromboembolic events could also occu

Table 2. Frequency of adverse reactions in placebo-controlled clinical trials (raloxifene 60 mg/day).

Term	Osteoporosis treatment Frequency (%)	Osteoporosis Prevention Frequency (%)	Coronary Heart Disease or at Increased Risk for CHD Frequency (%)
vasodilatation/ hot flush	9.7	24.3	7.8
superficial thrombophlebitis	1.3	0.2 ^a	1.0
leg cramps/ muscle spasms	7.0	5.5	12.1
peripheral edema	5.2	3.1	14.1
cholelithiasis	1.5 ^b	1.0 ^b	3.3 ^c

^a reported for 1 raloxifene-treated patient.

^b Raloxifene did not separate statistically from placebo in the osteoporosis treatment and prevention clinical trials.

Cholecystectomy rates for raloxifene (2.3%) were not statistically significantly different from placebo(2.0%).

4.9 Overdose

Daily doses of 600 mg administered during an 8 week study and 120 mg, used in clinical trials in more than 2,500 postmenopausal women for 3 years, were well tolerated.

In postmarketing spontaneous reports, overdose has been reported very rarely (less than 1 out of 10,000 [<0.01%] patients treated). The highest overdose has been approximately 1.5 grams. No fatalities associated with overdose have been reported. In adults, symptoms reported in patients who took more than 120 mg as a single ingestion included leg cramps and dizziness. In some cases, no adverse events were reported as a result of the overdose.

In accidental overdose in children under 2 years of age, the maximum reported dose has been 180 mg. In children, symptoms reported included ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, as well as elevation in alkaline phosphatase. There is no specific antidote for raloxifene.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: Raloxifene is a benzothiophene derivative which acts as Selective Estrogen Receptor Modulator (SERM). ATC code: G03X C01

odulator (SERM), raloxifene has vities on tissues responsive to one and partially on cholesterol _DL-cholesterol), but not in the reast tissues.

those of estrogen, are mediated rogen receptors and regulation of ts in differential expression of multiple nt tissues. Recent data suggests ulate gene expression by at least two tissue-, and/or gene- specific.

which occurs at menopause, leads tion, bone loss and risk of fracture. e first 10 years after menopause when the compensatory increase in bone formation is inadequate to keep up with resorptive losses. Other risk factors which may lead to lopment of osteoporosis include early menopause; osteopenia 1 SD below peak bone mass); thin body build; Caucasian or nnic origin; and a family history of osteoporosis. Replacement generally reverse the excessive resorption of bone. In opausal women, CELVISTA reduces the incidence of fractures, s bone mass and increases bone mineral density (BMD).

Effects on the endometrium

In clinical trials, CELVISTA did not stimulate the postmenopausal uterine endometrium. Compared to placebo, raloxifene was not associated with spotting or bleeding or endometrial hyperplasia. Nearly 3,000 transvaginal ultrasound (TVUs) examinations were evaluated from 831 women in all dose groups. Raloxifene treated women consistently had an endometrial thickness which was indistinguishable from placebo. After 3 years of treatment, at least a 5 mm increase in endometrial thickness, assessed with transvaginal ultrasound, was observed in 1.9 % of the 211 women treated with raloxifene 60 mg/day compared to 1.8 % of the 219 women who received placebo. There were no differences between the raloxifene and placebo groups with respect to the incidence of reported uterine bleeding.

Endometrial biopsies taken after six months therapy with CELVISTA 60 mg daily demonstrated non- proliferative endometrium in all patients. In addition, in a study with 2.5 x the recommended daily dose of CELVISTA there was no evidence of endometrial proliferation and no increase in uterine volume.

In the osteoporosis treatment trial, endometrial thickness was evaluated annually in a subset of the study population (1,644 patients) for 4 years. Endometrial thickness measurements in CELVISTA treated women were not different from baseline after 4 years of therapy. There was no difference between CELVISTA and placebo treated women in the incidences of vaginal bleeding (spotting) or vaginal discharge. Fewer CELVISTA treated women than placebo treated women required surgical intervention for uterine prolapse. Safety information following 3 years of raloxifene treatment suggests that raloxifene treatment does not increase pelvic floor relaxation and pelvic floor surgery.

After 4 years, raloxifene did not increase the risk of endometrial or ovarian cancer. In postmenopausal women who received raloxifene treatment for 4 years, benign endometrial polyps were reported in 0.9% compared to 0.3% in women who received placebo treatment.

Effects on breast tissue

CELVISTA does not stimulate breast tissue. Across all placebo-controlled trials, CELVISTA was indistinguishable from placebo with regard to frequency and severity of breast symptoms (no swelling, tenderness and breast pain).

Over the 4 years of the osteoporosis treatment trial (involving 7705 patients), CELVISTA treatment compared to placebo reduced the risk of total breast cancer by 62% (RR 0.38; CI 0.21, 0.69), the risk of invasive breast cancer by 71% (RR 0.29, Cl 0.13, 0.58) and the risk of invasive estrogen receptor (ER) positive breast cancer by 79% (RR 0.21, Cl 0.07, 0.50). CELVISTA has no effect on the risk of ER negative breast cancers. These observations support the conclusion that raloxifene has no intrinsic estrogen agonist activity in breast tissue. The effect of CELVISTA on breast cancer beyond 4 years is unknown.

Raloxifene has no proliferative effect on breast tissue. Across all placebo-controlled trials, raloxifene was indistinguishable from placebo with regard to frequency and severity of breast symptoms. In dinical trials, there was a decreased incidence of invasive breast cancer observed with raloxifene therapy.

Effects on cognitive function

No adverse effects on cognitive function have been seen.

5.2 Pharmacokinetic properties Absorption

Raloxifene is absorbed rapidly after oral administration. Approximately 60 % of an oral dose is absorbed. Presystemic glucuronidation is extensive. Absolute bioavailability of raloxifene is 2 %. The time to reach average maximum plasma concentration and bioavailability are functions of systemic interconversion and enterohepatic cycling of raloxifene and its glucuronide metabolites.

Distribution

Raloxifene is distributed extensively in the body. The volume of distribution is not dose dependent. Raloxifene is strongly bound to plasma proteins (98-99 %).

Metabolism

Raloxifene undergoes extensive first pass metabolism to the glucuronide conjugates: raloxifene-4'. glucuronide, raloxifene-6-glucuronide, and raloxifene-6,4'.diglucuronide. No other metabolites have been detected. Raloxifene comprises less than 1 % of the combined concentrations of raloxifene and the glucuronide metabolites. Raloxifene levels are maintained by enterohepatic recycling, giving a plasma half-life of 27.7 hours.

Results from single oral doses of raloxifene predict multiple dose pharmacokinetics. Increasing doses of raloxifene result in slightly less than proportional increase in the area under the plasma time concentration curve (AUC).

Excretion

The majority of a dose of raloxifene and glucuronide metabolites are excreted within 5 days and are found primarily in the faeces, with less than 6 % excreted in urine.

Special populations

Renal insufficiency - Less than $6\,\%$ of the total dose is eliminated in urine. In a population pharmacokinetic study, a 47 % decrease in lean body mass adjusted creatinine clearance resulted in a 17 % decrease in raloxifene clearance and a 15 % decrease in the clearance of raloxifene conjugates.

Hepatic insufficiency - The pharmacokinetics of a single dose of

In a study of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, overall mortality, including overall cardiovascular mortality, or stroke, compared to placebo. However, there was an increase in death due to stroke in women assigned to raloxifene.

The incidence of stroke mortality was 2.2 per 1000 women per year for raloxifene versus 1.5 per 1000 women per year for placebo (see section 4.8). This finding should be considered when prescribing raloxifene for postmenopausal women with a history of stroke or other significant stroke risk factors, such as transient ischemic attack or atrial fibrillation.

There is no evidence of endometrial proliferation. Any uterine bleeding during CELVISTA therapy is unexpected and should be fully investigated by a specialist. The two most frequent diagnoses associated with uterine bleeding during raloxifene treatment were endometrial atrophy and benign endometrial polyps. In postmenopausal women who received raloxifene treatment for 4 years, benign endometrial polyps were reported in 0.9% compared to 0.3% in women who received placebo treatment.

Raloxifene is metabolised primarily in the liver. Efficacy of raloxifene has not been studied in patients with impaired liver function. Single doses of raloxifene given to patients with cirrhosis and mild hepatic impairment (Child-Pugh class A) with total serum bilirubin ranging from 0.6 to 2.0 mg/dL produced plasma concentrations of raloxifene which were approximately 2.5 times higher than the controls. The increase correlated with total bilirubin concentrations. Until safety and efficacy have been evaluated further in patients with hepatic insufficiency, the use of CELVISTA is not recommended in this patient population. Serum total bilirubin, gamma-glutamyl transferase, alkaline phosphatase, ALT and AST should be closely monitored during treatment if elevated values are observed.

Estrogen-induced hypertriglyceridemia : In patients with a history of oral estrogen-induced hypertriglyceridemia (> 5.6 mmol/L), raloxifene may be associated with a marketed increase in serum triglycerides. Patients with this medical history should have serum triglycerides monitored when taking raloxifene.

The safety of CELVISTA in patients with breast cancer has not been adequately studied. No data are available on the concomitant use of CELVISTA and agents used in the treatment of early or advanced breast cancer. Therefore, CELVISTA should be used for osteoporosis treatment and prevention only after the treatment of breast cancer, including adjuvant therapy, has been completed.

Concurrent Use of Systemic Hormone Therapy: Safety information regarding the concurrent use of raloxifene and systemic hormone therapy (estrogen with or without progestin) is limited and therefore concomitant use of raloxifene with systemic estrogen is not recommended.

CELVISTA is not effective in reducing vasodilatation (hot flushes), or other symptoms of the menopause associated with estrogen deficiency.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine.

There is no indication for use of raloxifene in males.

4.5 Interaction with other medicinal products and other forms of interaction

Concurrent administration of either calcium carbonate or aluminium and magnesium-hydroxide containing antacids do not affect the systemic exposure of raloxifene.

Co-administration of raloxifene and warfarin or other coumarin derivatives does not alter the pharmacokinetics of either compound. However, modest decreases in the prothrombin time have been observed, and if raloxifene is given concurrently with warfarin or other coumarin derivatives, the prothrombin time should be monitored. Effects on prothrombin time may develop over several weeks if CELVISTA treatment is started in patients who are already on coumarin anticoagulant therapy.

Raloxifene has no effect on the pharmacokinetics of methylprednisolone given as a single dose.

Raloxifene does not affect the steady-state AUC of digoxin. The Cmax of digoxin increased by less than 5 %.

The influence of concomitant medication on raloxifene plasma concentrations was evaluated in the prevention and treatment trials. Frequently co-administered medicinal products included: paracetamol. non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines. No clinically relevant effects of the co-administration of the agents on raloxifene plasma concentrations

Musculoskeletal and Connective Tissue Disorders	the devel	
Common: Leg cramps	(at least 1	
Reproductive System and Breast Disorders Common: Mild breast symptoms such as pain, enlargement and tenderness.	Asian eth	
General Disorders and Administration Site Conditions Very common: Flu syndrome Common: Peripheral oedema		
Investigations	of the spi	
Very common: Increased blood pressure	normal yc	

^a Term(s) included based on postmarketing experience.

c. Description of selected adverse reactions

Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in CELVISTA patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % CELVISTA and 18.2 % placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6 % for CELVISTA and 7.1 % placebo). This undesirable reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.

In a study of 10,101 postmenopausal women with documented coronary heart disease or at increased risk for coronary events (RUTH), the occurrence of vasodilatation (hot flushes) was 7.8 % in the raloxifene-treated patients and 4.7 % in the placebo-treated patients Across all placebo-controlled clinical trials venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis occurred at a frequency of approximately 0.8 % or 3.22 cases per 1,000 patient years. A relative risk of 1.60 (CI 0.95, 2.71) was observed in CELVISTA treated patients compared to placebo. The risk of a thromboembolic event was greatest in the first four months of therapy. Superficial vein thrombophlebitis occurred in a frequency of less

In the RUTH study, venous thromboembolic events occurred at a frequency of approximately 2.0 % or 3.88 cases per 1.000 patient-years in the raloxifene group and 1.4 % or 2.70 cases per 1,000 patient-years in the placebo group. The hazard ratio for all VTE events in the RUTH study was HR = 1.44 (1.06 – 1.95). Superficial vein thrombophlebitis occurred in a frequency of 1 % in the raloxifene group and 0.6 % in the placebo group.

In the RUTH study, raloxifene did not affect the incidence of stroke, compared to placebo. However, there was an increase in death due to stroke in women assigned to raloxifene. The incidence of stroke mortality was 2.2 per 1,000 women per year for raloxifene versus 1.5 per 1,000 women per year for placebo (see section 4.4). During an average follow-up of 5.6 years, 59 (1.2%) raloxifene-treated women died due to a stroke compared to 39 (0.8%) placebo-treated women. Another undesirable reaction observed was leg cramps (5.5 % for CELVISTA, 1.9 % for placebo in the prevention population and 9.2 % for CELVISTA, 6.0 % for placebo in the treatment population).

In the RUTH study, leg cramps were observed in 12.1 % of raloxifene-treated patients and 8.3 % of placebo-treated patients. Flu syndrome was reported by 16.2 % of CELVISTA treated patients and 14.0 % of placebo treated patients. One further change was seen which was not statistically significant

(p > 0.05), but which did show a significant dose trend. This was of peripheral oedema which occurred in the prevention population at an incidence of 3.1 % for CELVISTA and 1.9 % for placebo; and in the treatment population occurred at an incidence of 7.1 % for CELVISTA and 6.1 % for placebo.

In the RUTH study, peripheral oedema occurred in 14.1% of the raloxifene-treated patients and 11.7 % of the placebo-treated patients, which was statistically significant.

Slightly decreased (6-10 %) platelet counts have been reported during raloxifene treatment in placebocontrolled clinical trials of raloxifene in osteoporosis

Rare cases of moderate increases in AST and/or ALT have been reported where a causal relationship to raloxifene cannot be excluded. A similar frequency of increases was noted among placebo patients.

In a study (RUTH) of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an additional adverse reaction of cholelithiasis occurred in 3.3 % of patients treated with raloxifene and 2.6 % of patients treated with placebo. Cholecystectomy rates for raloxifene (2.3%) were not statistically significantly different from placebo (2.0 %). CELVISTA (n = 317) was compared with continuous combined (n = 110)

hormone replacement therapy (HRT) or cyclic (n = 205) HRT patients in some clinical trials. The incidence of breast symptoms and uterine bleeding in raloxifene treated women was significantly lower than in women treated with either form of HRT.

CLINICAL TRIAL DATA:

Vasodilatation (hot flashes or hot flushes) was common in placebo-treated patients, and was modestly increased in raloxifene patients. The majority of adverse reactions occurring during clinical trials have been mild and have not required discontinuation of therapy.

n these risk factors, prevention of osteoporosis with CELVISTA ed for women within ten years of menopause, with BMD ine between 1.0 and 2.5 SD below the mean value of a normal young population, taking into account their high lifetime risk for osteoporotic fractures. Likewise, CELVISTA is indicated for the treatment of osteoporosis or established osteoporosis in women with BMD of the spine 2.5 SD below the mean value of a normal young population and/ or with vertebral fractures, irrespective of BMD.

i) Incidence of fractures. In a study of 7,705 postmenopausal women with a mean age of 66 years and with osteoporosis or osteoporosis with an existing fracture, CELVISTA treatment for 3 years reduced the incidence of vertebral fractures by 47 % (RR 0.53, Cl 0.35, 0.79; p < 0.001) and 31 % (RR 0.69, Cl 0.56, 0.86; p < 0.001) respectively. Forty five women with osteoporosis or 15 women with osteoporosis with an existing fracture would need to be treated with CELVISTA for 3 years to prevent one or more vertebral fractures. CELVISTA treatment for 4 years reduced the incidence of vertebral fractures by 46% (RR 0.54, Cl 0.38, 0.75) and 32% (RR 0.68, Cl 0.56, 0.83) in patients with osteoporosis or osteoporosis with an existing fracture respectively. In the 4th year alone, CELVISTA reduced the new vertebral fracture risk by 39% (RR 0.61, CI 0.43, 0.88). During the 4th year, patients were permitted the concomitant use of bisphosphonates, calcitonin and fluorides. An effect on extravertebral fractures has not been demonstrated. All patients in this study received calcium and vitamin D supplementation.

In the RUTH study overall clinical fractures were collected as a secondary endpoint. Celvista reduced the incidence of clinical vertebral fractures by 35% compared with placebo (HR 0.65, CI 0.47 0.89). These results may have been confounded by baseline differences in BMD and vertebral fractures. There was no difference between treatment groups in the incidence of new nonvertebral fractures. During the whole length of the study concomitant use of other bone-active medications was permitted.

ii) Bone Mineral Density (BMD): The efficacy of CELVISTA once daily in postmenopausal women aged up to 60 years and with or without a uterus was established over a two-year treatment period. The women were 2 to 8 years postmenopausal. Three trials included 1,764 postmenopausal women who were treated with CELVISTA or placebo. In one of these trials the women had previously undergone hysterectomy. CELVISTA produced significant increases in bone density of hip and spine as well as total body mineral mass compared to placebo. This increase was generally a 2 % increase in BMD compared to placebo. A similar increase in BMD was seen in the treatment population. In the prevention trials, the percentage of subjects experiencing an increase or decrease in BMD during raloxifene therapy was: for the spine 37 % decreased and 63 % increased; and for the total hip 29 % decreased and 71 % increased.

iii) Calcium kinetics. CELVISTA and estrogen affect bone remodelling and calcium metabolism similarly. CELVISTA was associated with reduced bone resorption and a mean positive shift in calcium balance of 60 mg per day, due primarily to decreased urinary calcium losses.

iv) Histomorphometry (bone quality). In a study comparing CELVISTA with estrogen, bone from patients treated with either medicinal product See label. was histologically normal, with no evidence of mineralisation defects, woven bone or marrow fibrosis.

Raloxifene decreases resorption of bone and returns bone turnover to the premenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of bone turnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in BMD and decreases in the incidence of fractures

b) Effects on lipid metabolism and cardiovascular risk

Clinical trials showed that a 60 mg daily dose of CELVISTA significantly decreased total cholesterol (3 to 6 %), and LDL cholesterol (4 to 10 %). Women with the highest baseline cholesterol levels had the greatest decreases. HDL cholesterol and triglyceride concentrations did not change significantly. After 3 years therapy CELVISTA decreased fibrinogen (6.71 %). In the osteoporosis treatment study, significantly fewer CELVISTA-treated patients required initiation of hypolipidaemic therapy compared to placebo.

CELVISTA therapy for 8 years did not significantly affect the risk of cardiovascular events in patients enrolled in the osteoporosis treatment study. Similarly, in the RUTH study, raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, stroke or overall mortality, including overall cardiovascular mortality, compared to placebo (for the increase in risk of fatal stroke see section 4.4)

The relative risk of venous thromboembolic events observed during raloxifene treatment was 1.60 (Cl 0.95, 2.71) when compared to placebo, and was 1.0 (Cl 0.3, 6.2) when compared to estrogen or hormonal replacement therapy. The risk of a thromboembolic event was greatest in the first four months of therapy.

Pugh class A) have been compared to that in healthy individuals. Plasma raloxifene concentrations were approximately 2.5-fold higher than in controls and correlated with bilirubin concentrations.

5.3 Preclinical safety data

In a 2-year carcinogenicity study in rats, an increase in ovarian tumors of granulosa/theca cell origin was observed in high-dose females (279 mg/kg/day). Systemic exposure (AUC) of raloxifene in this group was approximately 400 times that in postmenopausal women administered a 60-mg dose. In a 21-month carcinogenicity study in mice, there was an increased incidence of testicular interstitial cell tumours and prostatic adenomas and adenocarcinomas in males given 41 or 210 mg/kg, and prostatic leiomyoblastoma in males given 210 mg/ kg. In female mice, an increased incidence of ovarian tumours in animals given 9 to 242 mg/kg (0.3 to 32 times the AUC in humans) included benign and malignant tumours of granulosa/theca cell origin and benign tumours of epithelial cell origin. The female rodents in these studies were treated during their reproductive lives, when their ovaries were functional and highly responsive to hormonal stimulation. In contrast to the highly responsive ovaries in this rodent model, the human ovary after menopause is relatively unresponsive to reproductive hormonal stimulation.

Raloxifene was not genotoxic in any of the extensive battery of test systems applied.

The reproductive and developmental effects observed in animals are consistent with the known pharmacological profile of raloxifene. At doses of 0.1 to 10 mg/kg/day in female rats, raloxifene disrupted estrous cycles of female rats during treatment, but did not delay fertile matings after treatment termination and only marginally reduced litter size, increased gestation length, and altered the timing of events in neonatal development. When given during the preimplantation period, raloxifene delayed and disrupted embryo implantation resulting in prolonged gestation and reduced litter size but development of offspring to weaning was not affected. Teratology studies were conducted in rabbits and rats. In rabbits, abortion and a low rate of ventricular septal defects (20.1 mg/kg) and hydrocephaly (210 mg/kg) were seen. In rats retardation of foetal development, wavy ribs and kidney cavitation occurred (≥1 mg/kg).

Raloxifene is a potent antiestrogen in the rat uterus and prevented growth of estrogen-dependent mammary tumours in rats and mice.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet Core: Povidone, polysorbate 80, anhydrous lactose, lactose monohydrate, crospovidone, magnesium stearate.

Tablet coating: Titanium dioxide (E 171), polysorbate 80, hypromellose, macrogol 400, carnauba wax.

6.2 Incompatibilities

Not applicable.

6.3 Shelf-life

6.4 Special precautions for storage

Store below 30°C. Store in a dry place. Do not freeze. Protect from excessive heat and sunlight.+

6.5 Nature and content of container

CELVISTA tablets are packed either in PVC blisters, Adar blisters or in high density polyethylene bottles. Blister boxes contain 14, 28, or 84 tablets. Bottles contain 100 tablets.

6.6 Instructions for use and handling

No special requirements

7. Marketing Authorization Holder

Alvogen (Thailand) Limited, Bangkok, Thailand

8. Marketing Authorization Number

Refer to outer carton

9. Date of Authorization

6 Aug 2020

10. Date of revision of the text

July 2021